- A new SARS-CoV-2 assay is now available to antibody and vaccine researchers worldwide
- Characterize and monitor the immunity of COVID-19 patients

In this webinar, we discuss a highly accurate assay for simultaneously measuring the concentration and binding of IgG, IgM, and IgA antibodies to the Receptor Binding Domain (RBD) of SARS-CoV-2. This new label-free assay provides, for the first time, detailed resolution of the immune response of patients recovering from COVID-19 in a single assay and represents a significant development for clinical research teams studying immune responses to SARS-CoV-2.

The results we share represent a breakthrough for testing four parameters simultaneously in a single automated experiment on sera from up to 384 patients, using just 2 µL of serum from each patient. The outcome of the research is important for screening the immune status of COVID-19 patients and will be of great interest for studying population immunity, vaccine efficacy, and the status of neutralizing antibodies.

Presented by:
Leon Terstappen, MD, PhD, Professor, University of Twente
Judicaël Parisot, PhD, Senior Applications Scientist, Carterra

свернуть